ArticleFrontiers in molecular neuroscience2026
Systemic TGF-β1 reduction contributes to neuronal GLUT4 trafficking impairment in acute hepatic encephalopathy.
Article in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute liver failure disrupts cerebral glucose homeostasis and contributes to neurological manifestations of hepatic encephalopathy (HE). Neurons, which partly rely on the insulin-sensitive glucose transporter GLUT4, may be particularly vulnerable to systemic metabolic disturbances. Transforming growth factor beta 1 (TGF-β1), implicated in HE pathogenesis, is known to modulate insulin signaling in peripheral tissues; however, its role in neuronal glucose handling remains poorly defined. In this study, we investigated whether reduction of peripheral TGF-β1 in HE impairs the neuronal GLUT4 status and whether this effect can be reproduced by systemic TGF-β1 neutralization (sTGF-β1n) in healthy mice. Both HE and sTGF-β1n increased GLUT4 immunoreactivity in MAP2-positive neurons and promoted its accumulation within the neuronal cytoplasm. Together with unaltered GLUT4 membrane levels, this suggests defective cytosol-to-membrane translocation or mobilization of the transporter. These changes were accompanied by altered PI3K/Akt/PKCζ signaling in HE only, but decreased AMPK phosphorylation in both model treatments, indicating the latter route to be the common mediator of impaired regulation of GLUT4 trafficking. While hypoglycemia and hyperinsulinemia were observed only in the HE model, selective sTGF-β1n reproduces alterations in neuronal GLUT4 distribution in the absence of hypoglycemia and hyperinsulinemia accompanying HE in the present model, indicating that TGF-β1 deficiency
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.